Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor
Year: 2023
Type: conference-abstract
Source: Blood
Institutions: AstraZeneca (United Kingdom), AstraZeneca (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4389218883
